Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Sampson, Anna L ^a   Singer, Richard F ^b   Walters, Giles D ^b  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; C REACTIVE PROTEIN; COLCHICINE; CREATININE; FEBUXOSTAT; OXIPURINOL; PLACEBO; TOPIROXOSTAT; URIC ACID;

BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; EVIDENCE BASED MEDICINE; HEMODIALYSIS; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; URIC ACID LOWERING THERAPY; BLOOD; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; INCIDENCE; META ANALYSIS; MORTALITY; TIME FACTOR;

CARDIOVASCULAR DISEASES; CREATININE; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERURICEMIA; INCIDENCE; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; URIC ACID;

EID: 85032331406     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009460.pub2     Document Type: Review

References (61)

1. Bergamini C, Cicoira M, Rossi A, Cassater D, Zanolla L, Vassanelli C. Allopurinol lowers NT-proBNP plasma levels and improves diastolic function in heart failure patients: A double-blind, placebo-controlled study [abstract no: P4847]. European Heart Journal 2010;31(Suppl 1):849. [EMBASE: 70282775]6937975
2. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Pressure 2011;20(3):182-7. [MEDLINE: 21133824]6937977
3. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases 1982;41(1):59-65. [MEDLINE: 7039523]6937979
4. Gibson T, Simmonds HA, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Advances in Experimental Medicine & Biology 1980;122A:257-62. [MEDLINE: 6999847]6937980
5. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. American Journal of Kidney Diseases 2015;65(4):543-9. [MEDLINE: 25595565]6937982
6. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(8):1388-93. [MEDLINE: 20538833]6937983
7. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.[Erratum appears in Clin J Am Soc Nephrol. 2011 Dec;6(12):2901-2]. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(8):1887-94. [MEDLINE: 21784838]6937985
8. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Allopourinol effect on reducing proteinuria in diabetic retinopathy. Journal of Isfahan Medical School 2010;28(107):271-8. [EMBASE: 359535811]6937987
9. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iranian Journal of Kidney Diseases 2010;4(2):128-32. [MEDLINE: 20404423]6937988
10. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure. Expert Opinion on Investigational Drugs 2004;13(11):1509-16. [MEDLINE: 15500398]6937990
11. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. Journal of the American College of Cardiology 2009;53(25):2405. [MEDLINE: 19539154]6937991
12. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. Journal of the American College of Cardiology 2008;51(24):2301-9. [MEDLINE: 18549913]6937992
13. Sarris E, Bagiatudi G, Stavrianaki D, Salpigidis K, Siakotos M. Use of allopurinol in slowing the progression of chronic renal disease [abstract no: FP128]. Nephrology Dialysis Transplantation 2007;22(Suppl 6):vi61. 6937994
14. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney & Blood Pressure Research 2012;35(3):153-60. [MEDLINE: 22116196]6937996
15. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. American Journal of Kidney Diseases 2015;66(6):945-50. [MEDLINE: 26233732]6937998
16. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. American Journal of Kidney Diseases 2006;47(1):51-9. [MEDLINE: 16377385]6938000
17. Tuta L, Sburian A, Voinea F. Early allopurinol therapy slows progression of renal disease in predialysis patients with hyperuricemia [abstract no: MP261]. Nephrology Dialysis Transplantation 2006;21(Suppl 4):iv386. 6938002
18. Becker MA, Macdonald PA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes, Obesity & Metabolism 2013;15(11):1049-55. [MEDLINE: 23683134]6938004
19. Jackson RL, Hunt B, Macdonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients >/=65 years of age. BMC Geriatrics 2012;12:11. [MEDLINE: 22436129]6938005
20. Wells AF, MacDonald PA, Chefo S, Jackson RL. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskeletal Disorders 2012;13:15. [MEDLINE: 22316106]6938006
21. NCT00174915. A phase 3, randomized, multicenter, allopurinol and placebo-controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout. clinicaltrials.gov/ct2/show/NCT00174915 (first received 9 September 2005). 6938008
22. Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circulation Journal 2013;77(8):2043-9. [MEDLINE: 23676888]6938010
23. Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). Journal of Cardiology 2015;66(4):298-303. [MEDLINE: 25649025]6938011
24. Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Research & Therapy 2013;15(5):R137. [MEDLINE: 24286509]6938013
25. Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Research & Therapy 2014;16(2):R60. [MEDLINE: 24588936]6938014
26. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306(7):711-20. [MEDLINE: 21846852]6938015
27. Sundy JS, Becker MS, Huang WY, Waltrip RW, Chandraker AK. Treatment failure gout: efficacy and safety of pegloticase in phase 3 trials [abstract no: 1471]. American Journal of Transplantation 2009;9(Suppl 2):600. 6938016
28. Yood RA, Ottery FD, Irish W, Wolfson M. Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. BMC Research Notes 2014;7:54. [MEDLINE: 24447425]6938017
29. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical & Experimental Nephrology 2015;19(6):1044-53. [MEDLINE: 25676011]6938019
30. Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, et al. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatology International 2014;34(1):101-9. [MEDLINE: 24026528]6938021
31. Whelton A, MacDonald P, Lloyd E, Lademacher C. The long-term stability of renal function in hyperuricemic subjects with gout treated with febuxostat [abstract no: SA-PO918]. Journal of the American Society of Nephrology 2007;18(Abstracts):545A. 6938023
32. Whelton A, MacDonald PA, Hunt BJ, Joseph-Ridge N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in patients with a history of nephrolithiasis [abstract no: F-PO894]. Journal of the American Society of Nephrology 2006;17(Abstracts):525A. 6938024
33. Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clinical & Experimental Nephrology 2014;18(6):876-84. [MEDLINE: 24448692]6938026
34. Saag KG, Becker MA, Whelton A, MacDonald PA, Zhou Y, Gunawardhana L. Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: A randomized controlled trial [abstract no: 1178]. Arthritis & Rheumatism 2013;65(Suppl 10):S498-9. [EMBASE: 71318653]6938028
35. Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clinical Drug Investigation 2015;35(12):823-31. [MEDLINE: 26482071]6938030
36. Tani S, Nagao K, Hirayama A. Febuxostat, a xanthine oxidase inhibitor, may improve cardiorenal interaction: a randomized controlled pilot study [abstract]. European Heart Journal 2014;35(Suppl 1):904-5. [EMBASE: 71650121]6938031
37. Tani S, Takahashi A, Nagao K, Hirayama A. Febuxostat - a xanthine oxidase inhibitor - may improve cardiorenal interaction: a randomized controlled pilot study [abstract]. Circulation 2014;130(Suppl 2):A9432. [EMBASE: 71712984]6938032
38. Tuta L, Stanigut A. Allopurinol therapy for hyperuricemia reduces inflammation and progression of renal disease in moderate chronic kidney disease [abstract no: SP148]. Nephrology Dialysis Transplantation 2014;29(Suppl 3). [EMBASE: 71491775]6938034
39. The CKD-FIX Trial: controlled trial of slowing of kidney disease progression from the inhibition of xanthine oxidase. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343216 (first received 19 July 2011). 6938036
40. Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, et al. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. Trials [Electronic Resource] 2014;15(1):26. [MEDLINE: 24433285]6938038
41. Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Current Diabetes Reports 2013;13(4):550-9. [MEDLINE: 23649945]6938040
42. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. American Journal of Kidney Diseases 2010;56(2):264-72. [MEDLINE: 20385436]
43. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation 2014;29(2):406-13. [MEDLINE: 24042021]
44. Cameron JS, Simmonds HA. Uric acid and the kidney. Oxford Textbook of Clinical Nephrology. 3rd Edition. Vol. 2, Oxford University Press, 2005:1059-73.
45. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47. [MEDLINE: 17986697]
46. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Current Pharmaceutical Design 2005;11(32):4161-75. [MEDLINE: 16375738]
47. Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008;359(17):1811-21. [MEDLINE: 18946066]
48. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6. [MEDLINE: 18436948]
49. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. American Journal of Medicine 1967;42(1):27-37. [MEDLINE: 6016478]
50. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
51. Higgins JPT, Green S [editors]. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Kang D, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002;13(12):2888-97. [MEDLINE: 12444207]
53. Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, et al. Effect of lowering uric acid on renal disease in type 2 diabetic db/db mice. American Journal of Physiology - Renal Physiology 2009;297(2):F481-8. [MEDLINE: 19458127]
54. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80. [MEDLINE: 21840587]
55. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. Journal of Rheumatology 2000;27(4):1045-50. [MEDLINE: 10782835]
56. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81. [MEDLINE: 20483451]
57. Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid - A uremic toxin?. Blood Purification 2006;24(1):67-70. [MEDLINE: 16361844]
58. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
59. Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Uaratanawong S, Suraamornkul S, Angkeaw S, Uaratanawong R. Prevalence of hyperuricemia in Bangkok population. Clinical Rheumatology 2011;30(7):887-93. [MEDLINE: 21302126]
61. Winearls CG, Haynes R, Glassock R. CKD staging - evolution not revolution. Nefrologia 2010;30(5):493-500. [MEDLINE: 20882090]